Danaher to acquire Masimo for $9.9 billion in all-cash deal

Danaher has agreed to acquire Masimo for $9.9 billion in cash, or $180 per share, representing 18 times projected 2027 EBITDA. The deal is expected to add $0.15 to $0.20 to adjusted EPS in the first full year. Masimo will operate as a standalone unit within Danaher’s Diagnostics segment, with the transaction closing in the second half of 2026.